Evaluation of MicroRNA-125b-5p and Transcription Factors BLIMP1 and IRF4 Expression in Unsolved Common Variable Immunodeficiency Patients.


Journal

Iranian journal of allergy, asthma, and immunology
ISSN: 1735-5249
Titre abrégé: Iran J Allergy Asthma Immunol
Pays: Iran
ID NLM: 101146178

Informations de publication

Date de publication:
08 Dec 2021
Historique:
received: 28 03 2021
accepted: 23 06 2021
entrez: 18 12 2021
pubmed: 19 12 2021
medline: 8 3 2022
Statut: epublish

Résumé

Common variable immunodeficiency (CVID) is the most prevalent form of symptomatic primary humoral immunodeficiencies characterized by failure in the final differentiation of B lymphocytes. The majority of CVID cases have no identified genetic defect, and epigenetic alteration could be involved in the pathogenesis of CVID. Hence, we aimed to evaluate the expression of hsa-miR-125b-5p -and, B lymphocyte-induced maturation protein-1(BLIMP-1) and interferon regulatory protein-4 (IRF-4) in a group of CVID patients with no definitive genetic diagnosis in comparison with healthy individuals. Ten CVID patients (all known genes excluded) and 10 age and sex-matched healthy controls participated in the study. B lymphocytes were isolated and expression of miR-125b-5p, IRF4, and BLIMP1 were evaluated by real-time polymerase chain reaction (RT-PCR). Moreover, B cell subsets were analyzed by flow cytometry. The results showed that the relative expression of miR-125b-5p in CVID patients was increased while it was decreased for the BLIMP1 and IRF4 transcription factors compared with the healthy controls. Although a reduction was observed in switched and non-switched memory B cells among all high-miR patients, these subsets were decreased in patients with normal miR expression (71.0% and 85.0%, respectively). Our results suggest that overexpression of miR-125b-5p affects the terminal differentiation of B cells in a selected group of CVID patients by downregulating the BLIMP-1 gene and more intensively for the IRF-4 gene expressions.

Identifiants

pubmed: 34920653
doi: 10.18502/ijaai.v20i6.8021
doi:

Substances chimiques

Biomarkers 0
Interferon Regulatory Factors 0
MIRN125 microRNA, human 0
MicroRNAs 0
interferon regulatory factor-4 0
PRDM1 protein, human 138415-26-6
Positive Regulatory Domain I-Binding Factor 1 EC 2.1.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-710

Auteurs

Zahra Hamidi Esfahani (Z)

Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran AND Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran. zari.h.1991@gmail.com.

Reza Yazdani (R)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran. reza_yazdani86@yahoo.com.

Sepideh Shahkarami (S)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran AND Department of Pediatrics, University Hospital, Ludwig-Maximilians-Universität München (LMU), Munich, Germany AND Medical Genetics Network (Megene), Universal Scientific Education and Research Network (USERN), Tehran, Iran. shahkarami_s@yahoo.com.

Fateme Babaha (F)

Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran AND Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran. fbabaha@gmail.com.

Hassan Abolhassani (H)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran AND Department of Laboratory Medicine, Division of Clinical Immunology, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden AND Department of Biosciences and Nutrition, Division of Clinical Immunology, Karolinska Institute, Huddinge, Sweden. abolhassanih@yahoo.com.

Maryam Sadr (M)

Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran. m.sadr62@gmail.com.

Ali Akbar Pourfathollah (AA)

Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Pourfa@modares.ac.ir.

Asghar Aghamohammadi (A)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran. aghamohammadi@sina.tums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH